Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3505728 | 0.91 | MGLL (0.48) | NR1H2ALOX5APFEN1CHEK2KDM4E | |
| SCHEMBL4102433 | 0.89 | RBP4 (0.46) | NR1H2ALOX5APFEN1 | |
| SCHEMBL4510139 | 0.89 | STS (0.47) | KDM4EPKMCSF1RGPR119STS | |
| SCHEMBL13419698 | 0.85 | GPR119 (0.50) | NR1H2ALOX5APFEN1CHEK2KDM4E | |
| SCHEMBL22265811 | 0.84 | KDM4E (0.54) | KDM4EPKMCSF1RGPR119STS | |
| SCHEMBL4369008 | 0.83 | ALDH1A1 (0.50) | KDM4EPKMCSF1RGPR119ALDH1A1 | |
| SCHEMBL27462772 | 0.83 | KDM1A (0.53) | NR1H2GPR119STSNPC1ALDH1A1 | |
| SCHEMBL19833795 | 0.82 | RBP4 (0.51) | KDM4EPKMCSF1RGPR119STS | |
| SCHEMBL4372620 | 0.82 | CSF1R (0.45) | CHEK2KDM4EPKMCSF1RGPR119 | |
| SCHEMBL19462318 | 0.82 | PDE4B (0.52) | NR1H2ALOX5APFEN1CHEK2STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | NR1H2 746/4885ALOX5AP 555/4885FEN1 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.